UCB's Global Corporate Website

This section is intended for media and financial analysts

Search Press releases

24 Feb 2023

Share Repurchase Program 2023 to cover UCB's Long Term Incentive Plans for employees

Read More
22 Feb 2023

UCB managed 2022 headwinds and is ready for 2023 launches

Read More
8 Feb 2023

FINTEPLA[®]▼ (fenfluramine) oral solution approved in the EU for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS)

Read More
18 Jan 2023

Annals of the Rheumatic Diseases Publishes Results from Two Bimekizumab Phase 3 Studies in Axial Spondyloarthritis

Read More
9 Jan 2023

UCB's financial update

Read More
6 Jan 2023

UCB announces rozanolixizumab BLA for the treatment of generalized myasthenia gravis filed with U.S. FDA and designated for Priority Review

Read More

Stay up-to-date on the latest news and information from UCB